12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

XEN402 regulatory update

Teva and Xenon said FDA granted Orphan Drug designation for XEN402 to treat pain associated with erythromelalgia. The pain product...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >